T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...
GlobalData on MSN13h
AstraZeneca secures first BTK approval in first-line mantle cell lymphomaThe approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback